Novo Nordisk Drug Outperformed Tirzepatide in Trials
The pharmaceutical company announced that its experimental diabetes treatment showed superior weight loss results.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you trust that newer weight-loss medications generally offer significant benefits over existing treatment options?
Novo Nordisk reported that its investigative drug CagriSema outperformed tirzepatide 5 mg in a phase 3 clinical trial. Participants receiving the treatment experienced higher rates of weight loss over 60 weeks while maintaining blood sugar control.
Why it matters
These results provide new clinical evidence for managing type 2 diabetes and weight loss. The trial data offers a direct comparison between emerging therapies, which may influence future treatment standards for patients.
In the REIMAGINE 5 study, CagriSema 1.0 mg/1.0 mg yielded 12.4% weight loss compared to 9.1% for tirzepatide 5 mg at 60 weeks. Glycated hemoglobin A levels were reduced by 1.71% with CagriSema versus 1.67% with tirzepatide.
The players
Novo Nordisk
This is a global healthcare company specializing in the research, development, and manufacturing of pharmaceutical products, particularly for diabetes and obesity.
Food and Drug Administration
This is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products in the United States.
The details
The REIMAGINE 5 study enrolled adults with type 2 diabetes whose condition was not adequately controlled by metformin or an SGLT2 inhibitor. Additionally, the REDEFINE 9 trial reported that CagriSema 1.0 mg/1.0 mg achieved a 21.0% weight reduction at 68 weeks, compared to 2.0% in the placebo group.
Timeline
December 2025: Novo Nordisk filed a new drug application with the FDA.
September 21, 2026: Topline phase 3 results were announced.
Q4 2026: An FDA decision is expected for the weight management application.
The Big Picture
This development follows the formal submission of an NDA to the FDA, marking a critical step in the regulatory review process for this drug. The filing initiates a rigorous evaluation period that will ultimately determine the commercial viability and market authorization of the treatment.
These results offer potential new options for patients struggling to manage type 2 diabetes and weight. Depending on future FDA approval, these findings may change the range of medications physicians can prescribe to improve long-term health outcomes.
The takeaway
Advancements in clinical trials demonstrate the increasing precision of pharmacological approaches to metabolic health. Patients should consult with their healthcare providers regarding the potential role of emerging treatments in their existing management plans.
What happens next
The Food and Drug Administration is expected to announce a final decision regarding the weight management application in the fourth quarter of 2026.
Further reading
For more information on current treatment standards and ongoing research, visit the Diabetes section.
Live Poll
Do you trust that newer weight-loss medications generally offer significant benefits over existing treatment options?
